Previous 10 | Next 10 |
Pressure BioSciences Inc. (OTCQB: PBIO) , a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced the publication of two scientific journal articles led by independent teams of scient...
Two Prestigious Research Centers Report PBI’s PCT Platform Delivers Superior Results for Protein Biomarker Discovery Studies from Preserved Cancer Biopsy Tissue Samples SOUTH EASTON, MA, Sept. 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pressure BioScie...
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2019) - Pressure BioSciences, Inc. (OTCQB: PBIO) announced two additional purchase orders for its revolutionary BaroShear™ K45 processing system. Based on the company's proprietary Ultra Shear Technology™ (UST™) pla...
Pressure BioSciences (OTCQB: PBIO) , a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life-sciences and other industries, recently executed a contract services agreement with a well-known biotherapeutics firm. An article discuss...
Pressure BioSciences Inc. (OTCQB: PBIO) , a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced its receipt of two additional purchase orders for its revolutionary BaroShear(TM) K45...
Company Forecasts All 12 Systems in Current Build Cycle Will Be Sold by September 30, 2019 and Reiterates Previous Guidance for More Than Doubling of Annual Revenue in 2020 SOUTH EASTON, MA, Aug. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Pressure BioSciences, Inc. (...
Pressure BioSciences, Inc. (PBIO) Q2 2019 Earnings Conference Call August 15, 2019 04:30 PM ET Company Participants Richard Schumacher - President & Chief Executive Officer Jeff Peterson - Chairman Conference Call Participants Jay Hetrick - J. Charles Assets Presentati...
Pressure BioSciences (OTCQB: PBIO) , a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced financial results for the second quarter ended June 30, 2019, provided a business update, ...
Pressure BioSciences ( OTC:PBIO ): Q2 GAAP EPS of -$2.22. More news on: Pressure BioSciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Record Consumables Sales, Strong Growth in BaroFold & UST Services, and Launch of Revolutionary CBD Processing System Highlight the 2019 Second Quarter; Company Believes Total Revenue Will More than Double in 2020 Investor Conference Call Scheduled for ...
News, Short Squeeze, Breakout and More Instantly...
Pressure BioSciences Inc Company Name:
PBIO Stock Symbol:
OTCMKTS Market:
Pressure BioSciences Inc Website:
Pressure BioSciences (OTCQB: PBIO) , a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services across global industries, today announced a partnership with Vita-Forte, the larg...
CANTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemul...
Pressure BioSciences (OTCQB: PBIO) , a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables and specialty process development and testing services across global industries, today announced that it will host a teleconference to update investors an...